Long-term clinical impact and cost-effectiveness of obeticholic acid for the treatment of primary biliary cholangitis

Hepatology

Volumn 65, Issue 3, 2017, Pages 920-928

  Samur, Sumeyye ^a,b   Klebanoff, Matthew ^a   Banken, Reiner ^c   Pratt, Daniel S ^a,b   Chapman, Rick ^c   Ollendorf, Daniel A ^c   Loos, Anne M ^c   Corey, Kathleen ^a,b   Hur, Chin ^a,b   Chhatwal, Jagpreet ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILIRUBIN; COLESTYRAMINE; HYDROXYZINE; OBETICHOLIC ACID; URSODEOXYCHOLIC ACID; CHENODEOXYCHOLIC ACID;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; CHOLANGITIS; CLINICAL OUTCOME; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER GRAFT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; MONOTHERAPY; MORTALITY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY BILIARY CHOLANGITIS; PRIORITY JOURNAL; PRURITUS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DOSE RESPONSE; DRUG ADMINISTRATION; ECONOMICS; FOLLOW UP; IMMUNOHISTOCHEMISTRY; NEEDLE BIOPSY; PATHOLOGY; PROSPECTIVE STUDY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME;

ADULT; BIOPSY, NEEDLE; CHENODEOXYCHOLIC ACID; CHOLANGITIS; COHORT STUDIES; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

EID: 85010805011     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.28932     Document Type: Article

References (33)

1. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181-1188.
2. Selmi C, Bowlus CL, Gershwin ME, Coppel RL. Primary biliary cirrhosis. Lancet 2011;377:1600-1609.
3. Ilyas JA, O'Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011;25:765-782.
4. Czul F, Peyton A, Levy C. Primary biliary cirrhosis: therapeutic advances. Clin Liver Dis 2013;17:229-242.
5. Khungar V, Goldberg DS. Liver transplantation for cholestatic liver diseases in adults. Clin Liver Dis 2016;20:191-203.
6. Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis. Lancet 2015;386:1565-1575.
7. Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut 2016;65:321-329.
8. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136:1281-1287.
9. Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology 2014;147:1338-1349; quiz e1315.
10. Poupon RE, Lindor KD, Cauch-Dudek K, Dickson ER, Poupon R, Heathcote EJ. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997;113:884-890.
11. Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med 2016;375:631-643.
12. Ludwig J, Dickson ER, McDonald GS. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 1978;379:103-112.
13. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020-1022.
14. Caballeria L, Pares A, Castells A, Gines A, Bru C, Rodes J. Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virus-related cirrhosis. Am J Gastroenterol 2001;96:1160-1163.
15. Arias E. United States life tables, 2011. National Vital Statistics Report 64. Washington, DC: US Department of Health and Human Services; 2015.
16. Bolier AR, Peri S, Oude Elferink RP, Beuers U. The challenge of cholestatic pruritus. Acta Gastroenterol Belg 2012;75:399-404.
17. Jones EA, Bergasa NV. The pruritus of cholestasis. Hepatology 1999;29:1003-1006.
18. Mayo M, Kremer AE, Beuers U, Marmon T, Hooshmand-Rad R, Pencek R, et al. Mitigation of pruritus during obeticholic acid treatment in patients with primary biliary cirrhosis: strategies and successes. Gastroenterology 2016;150(Suppl. 1):S1072.
19. Saab S, Hunt DR, Stone MA, McClune A, Tong MJ. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model. Liver Transpl 2010;16:748-759.
20. Prince M, Chetwynd A, Newman W, Metcalf JV, James OF. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 2002;123:1044-1051.
21. Centers for Medicare & Medicaid Services. Physician fee schedule. https://www.cms.gov/medicare/medicare-fee-for-service-payment/physicianfeesched/. Accessed May 1, 2016.
22. Truven Health Analytics. RedBook Online. 2016. http://www.redbook.com/redbook/online/
23. Hirschfield GM, Mason A, Luketic V, Lindor K, Gordon SC, Mayo M, et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2015;148:751-761.
24. Chong CAKY, Gulamhussein A, Heathcote EJ, Lilly L, Sherman M, Naglie G, et al. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003;98:630-638.
25. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth B, et al. Cost effectiveness of peginterferon-2b plus ribavirin versus interferon -2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425.
26. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG. Report of nationally representative values for the noninstitutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 2006;26:391-400.
27. Elbasha EH, Chhatwal J. Theoretical foundations and practical applications of within-cycle correction methods. Med Decis Making 2016;36:115-131.
28. Ali AH, Lindor KD. Obeticholic acid for the treatment of primary billiary cholangitis. Expert Opin Pharmacother 2016;17:1809-1815.
29. Corpechot C, Carrat F, Poupon R, Poupon RE. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002;122:652-658.
30. Pasha T, Heathcote J, Gabriel S, Cauch-Dudek K, Jorgensen R, Therneau T, et al. Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis. Hepatology 1999;29:21-26.
31. Boberg KM, Wisloff T, Kjollesdal KS, Stovring H, Kristiansen IS. Cost and health consequences of treatment of primary biliary cirrhosis with ursodeoxycholic acid. Aliment Pharmacol Ther 2013;38:794-803.
32. Institute for Clinical and Economic Review. Obeticholic acid for the treatment of primary biliary cholangitis: comparative clinical effectiveness, value, and value-based price benchmarks. https://icer-review.org/wp-content/uploads/2016/07/NECEPAC_OCA_PBC_Evidence_Report_FINAL.pdf. Published July 26, 2016.
33. Drummond MF, Wilson DA, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care 2007;23:36-42.